Vimarsana
Biggest News Aggregation in the World

Page 16 - Pharma Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Services Today - Breaking & Trending Today

Global Pharmaceutical Contract Manufacturing Market - Vimarsana News

Global Pharmaceutical Contract Manufacturing Market

Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The

Healthcare Trends & Transactions Q3 2023 | Bass, Berry & Sims PLC - Vimarsana News

Healthcare Trends & Transactions Q3 2023 | Bass, Berry & Sims PLC

After steadying during Q2, it appears the overall volume of deals in the healthcare industry declined in Q3 compared with Q2, and year-to-date 2023 is still down from last year. A...

Think Research Announces Agreement for Subsequent Advance Under Existing ... - Vimarsana News

Think Research Announces Agreement for Subsequent Advance Under Existing ...

Think Research Announces Agreement for Subsequent Advance Under Existing ...

NeoGenomics (NASDAQ:NEO) Price Target Raised to $17.00 at Morgan Stanley - Vimarsana News

NeoGenomics (NASDAQ:NEO) Price Target Raised to $17.00 at Morgan Stanley

NeoGenomics (NASDAQ:NEO – Free Report) had its target price upped by Morgan Stanley from $16.00 to $17.00 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has an equal weight rating on the medical research company’s stock. Other equities research analysts have also issued reports about the company. Piper Sandler […]

Los Angeles Capital Management LLC Buys Shares of 24,201 NeoGenomics, Inc. (NASDAQ:NEO) - Vimarsana News

Los Angeles Capital Management LLC Buys Shares of 24,201 NeoGenomics, Inc. (NASDAQ:NEO)

Los Angeles Capital Management LLC purchased a new position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 24,201 shares of the medical research company’s stock, valued at approximately $389,000. Several other large investors have also recently […]